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Summary.-Experiments were carried out to determine whether the enhancement
of alkylating-agent cytotoxicity seen after large single doses of misonidazole
(MISO) in mouse tumours can also be achieved by prolonged exposure to low MISO
levels similar to those which can be tolerated clinically.
The level in mouse blood plasma could be maintained at about 100jig/ml for 7 h
by injecting small doses of MISO every 1/2 h. The effect of this treatment in combina-
tion with cyclophosphamide (CY) or melphalan (L-PAM) was studied in the RIF-1
tumour, using regrowth delay and cell-survival cloning assays. In each case, pro-
longed exposure to low levels of MISO gave enhancement ratios very close to those
obtained with a large single dose. ERs of 16-2-0 were obtained with CY and 18-2.2
with L-PAM over the range of alkylating-agent doses used.
In experiments with CY the response of 2 normal-tissue systems, marrow and
WBC count, was also studied. No significant enhancement of CY damage occurred
in either case. In the L-PAM experiments the LD50/30 and WBC counts were deter-
mined as normal-tissue end points. Multiple MISO had no effect.
Our results show that levels of MISO which can be achieved safely in man yield
good enhancement of the tumour cytotoxicity of 2 widely used chemotherapeutic
agents without increasing the damage to normal tissues.
ELECTRON-AFFINIC AGENTS, such as the
2-nitroimidazole misonidazole [1-(2-nitro-
imidazole-l-yl)-3-methoxypropan-2-ol, Ro-
07-0582, MISO], have been shown to be
effective sensitizers ofthe cytotoxic effects
of radiation on hypoxic cells in vitro and
in tumours in vivo (Adams, 1977) and
clinical trials ofMISO in combinationwith
radiation therapy are in progress in many
centres.
Recently it has been shown that MISO is
capable ofsensitizing tumours in mice to a
variety of alkylating agents including
cyclophosphamide, melphalan and the
nitrosoureas (Rose et al., 1980; Clement
et al., 1980; Tannock, 1980; Martin et al.,
1981; Law et al., 1981; Twentyman, 1981;
Siemann, 1981; Mulcahy et al., 1981).
Although most of these authors have
found that the cytotoxicity of the alkyl-
ating agents to the normal tissues is
enhanced by MISO, almost all have
concluded that the enhancement of the
tumour response is greater than that of
the normal tissues, producing a therapeu-
tic gain. Tannock (1980), however, found
no therapeutic advantage for the com-
bined treatment of MISO with cyclo-
phosphamide (CY) or BCNU, but Law
et al. (1981) have suggested that this is
only true at high doses of the alkylating
agents, and that at lower doses there is
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greater sensitization of the tumour cells
than of the cells of the normal tissue.
These authors show further that the
therapeutic gain at moderate to low doses
of CY could be exploited by multiple
fractions ofthe combined treatments.
A major question not resolved by any
of the above studies is whether the
differential enhancement of the cyto-
toxicity of alkylating agents to tumour
cells would occur at clinically realistic
dose-levels of MISO. Most authors for
example have used MISO doses of 600-
1000 mg/kg, which produce plasma levels
of MISO 5-10 x those that can be
achieved in humans. In those studies in
which lower doses of MISO have been
used, the results have been equivocal.
Twentyman (1981) found that the sensi-
tization of the RIF-l and KHT tumours
to CY was considerably reduced at
300 mg/kg MISO, and although in our
own studies with the RIF-I rumour we
found significant sensitization of the
cytotoxicity of CY at MISO doses of 125
and 250 mg/kg, the effect was less than
that seen at higher doses of MISO. In his
study with the KHT sarcoma, Siemann
(1981) found a dose-modification factor
for CCNU toxicity of 1 9 with a MISO
dose of 250 mg/kg, but lower doses were
not tested. Thus it is far from clear
whether any useful enhancement of the
cytotoxicity of alkylating agents on tui-
mours will occur at the maximum plasma
concentrations of MISO that can be
achieved in humans (-' 150 ,ug/ml). On the
other hand, the plasma half-life of MISO
in the mouse is about one tenth that in
man, and it is therefore possible that
prolonged exposure of tumour cells to
MISO, even at relatively low doses,
might increase its sensitizing effect. In
the present experiments we have at-
tempted to answer this question by
simulating in the mouse the prolonged
low levels of MISO which can be tolerated
in humans, in order to determine whether
useful sensitization of the cytotoxicity of
CY on tumour cells might be achieved by
MISO in the clinic.
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MATERIALS AND METHODS
Tumour studies
The RIF-1 tumour used in the present
study is a nonimmunogenic sarcoma in its
syngeneic host, the C3H/Km mouse, and has
been developed for in vivo and in vitro
assay (Twentyman et al., 1980). Solid tumours
were used in 3-4 month old female C3H/Km
mice by inoculating 2 x 105 cells in a volume
of 0 05 ml, either into the base of the gastro-
cnemius muscle or intradermally in the
flank. Growth of the leg-implanted tumours
was followed by measuring 2 leg diameters
at right angles, and tumour volume was
estimated from a calibration curve for tu-
mour weight plotted as a function of the
product of the 2 leg diameters (Twentyman
et al., 1979). Drug treatments were given
when the tumours were 300-600 mg. The
volume of the flank tumours was followed by
measuring 3 mutually perpendicular dia-
meters of the tumour and using the formula:
ir/6 x d, x d2 x d3
The response to drug treatments was
investigated by 2 methods. For the re-
growth-delay assay, 10 mice were included
in each experiment group and tumours were
measured at 3 x per week. To compare
treatments, the number of days required to
reach 4 x the mean treatment volume was
determined from growth curves plotted for
each animal. Geometric means and standard
errors were calculated for each treatment
group.
For the cell-survival assay, tumours were
excised 24h after treatment. Two to 4 tumours
were pooled and a single-cell suspension
was prepared by mincing the tissue and
incubating it with an enzyme cocktail of
0-02%O collagenase, 0-02% DNAse and0.05%
pronase. The number of cells excluding
trypan blue was counted using a haemacyto-
meter (cell yield 2 x 108 cells/g) and appro-
priate dilutions were plated into polystyrene
Petri dishes containing complete Waymouth's
medium with 10% foetal calfserum. Colonies
of at least 50 cells were counted after 13
days' incubation at 37°C. The plating
efficiency (PE) for control tumours was
3000. Surviving fractions were calculated
using either PE or number of clonogenic
cells/g tumour. There was no significant
difference between the results obtained using
the 2 methods, so only surviving fractions
estimated from PE are shown in the figures.
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Normal-tissue studies
Marrow stem cells.-The effect of the drug
treatments on the survival of marrow stem
cells was studied using the spleen-colony
assay (Till & McCulloch, 1961). Marrow
cells flushed from the femurs of treated
C3H/Km mice (usually 4 mice per group)
were injected into the tail veins ofpreirradia-
ted recipients. Two dilutions of marrow cells
were always used, with 6 mice per dilution.
The number of colonies counted on the
spleens of these animals after 7-8 days was
used to determine the survival of injected
marrow cells.
White-cell counts.-Previous experiments
have shown that the number of WBC in
the peripheral blood declines for several
days after treatment with CY (Law et al.,
1981), reaching a minimum at about 4 days
before recovery begins. In the present
experiments 5,1j blood samples were taken
from the tails of mice (6 per group) 4 days
after MISO and CY treatments. The blood
was diluted in 95 ,ul of 2% glacial acetic
acid to lyse the red blood cells and counts
of total leucocytes were made. Results were
expressed as the number of cells/mm3
in the original blood sample.
LD50/30.-Normal-tissue toxicity in the
L-PAM study was assessed by determining
the number of animals dying within 30 days
after doses of 6-2-14 mg/kg L-PAM, with or
without multiple MISO. All the animals
bore the RIF-1 tumour in the leg. At the
lower doses of L-PAM animals had to be
killed before 30 days because their tumours
became large. Since none of the animals
showed any sign of sickness at these doses,
they were considered to be survivors for
analysis of the data. LD50 values and 95%
confidence limits were determined by logit
analysis. A similar experiment with non-
tumour-bearing mice was also performed.
10 mice per dose group were used.
Monitoring MISO levels.-Plasma (or whole
blood) levels of MISO were determined using
high-performance liquid chromatography
(HPLC) as follows. At regular intervals
during the MISO administrations, 10jzd
blood samples were collected from the tails
ofthe experimental mice in Microcap pipettes
(Drummond Scientific Co.), mixed with 40
pl distilled water and stored at -20°C.
They were subsequently analysed for MISO
and desmethyl MISO levels as described
previously (Workman et al., 1978).
Drug treatments
MISO and CY were dissolved in physio-
logical saline, but L-PAM had first to be
dissolved in ethanol and further diluted in
saline immediately before injection because
of its instability in aqueous solution. All
the drugs were injected i.p.
When given as a large single dose of 750
mg/kg, MISO was made up at a dilution of
25 mg/ml and injected at 0 03 ml/g body wt
30 min before CY or L-PAM injection. For
the multiple-injection schedule, 2 dilutions of
MISO were made for each experiment. In
combination with CY, a high priming dose
of 0-6 mmol/kg MISO was first given by
injecting 0 01 ml/g body wt of a 12mg/ml
solution. This was followed at 1/2 h intervals
by 14 doses of 0-15 mmol/kg, by injecting
0.01 ml/g of a 3 mg/ml solution. In the L-
PAM experiments, MISO doses were reduced
in an attempt to match the human drug
profile more closely. The priming dose was
reduced to 0-24 mmol/kg and the subsequent
doses reduced to 0-12 mmol/kg. The single
CY or L-PAM injections were given 4 h after
the first priming dose ofMISO, and immedia-
tely before the 9th MISO injection. The
time was chosen because in a preliminary
experiment we had found that 4 h gave the
maximum response, with no additional
sensitization at longer times.
RESULTS
Cyclophosphamide
Fig. 1 shows the response of the RIF-1
sarcoma (implanted i.m.) to various doses
of CY. The mice were injected with saline
(controls) or given repeated injections of
MISO every 30 min. For the latter group
the CY injection was given 4 h after the
start of the prolonged MISO exposure,
which was then continued for a further 3 h.
The lower panel ofFig. 1 shows the plasma
concentration of MISO in the repeatedly
injected group. It can be seen that it
closely simulates the levels found in
humans by Urtasun et al. (1977) following
a single oral dose of 7 g of MISO. Also
shown in the upper panel of Fig. 1 are the
data in the same experiment for the
response of the tumours to CY given
30 min after a single, large dose of MISO
(750 mg/kg).
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FIG. 2.-The effect ofsaline (0) or prolonged
MISO exposure (*) on the CY dose-
response curve for marrow stem cells
(CFU-S). Line was drawn through the
saline+CY data.
FIG. 1.-The effect of prior treatment with
saline (0, O1), a large single dose of 750
mg/kg MISO (-) or prolonged exposure
(15 fractions) to low-level MISO (0, *)
on the survival of RIF-1 tumour cells ex-
posed to a range of CY doses. The circles
and squares indicate two independent ex-
periments. Lines were drawn by eye
through the saline and the multiple-MISO
points (upper panel). Also shown (lower
panel) are the plasma levels achieved with
multiple MISO injections in one of these
experiments (0). The dashed line rep-
resents a typical human exposure after the
oral administration of 7 g MISO (Urtasun
et al., 1977).
Fig. 2 shows the response of marrow
stem cells (CFU-S) to various doses of CY
with or without prolonged MISO admin-
istration; animals were killed 24 h after
CY injection. The data points at CY doses
of up to 100 mg/kg were obtained from
the mice used for the tumour response in
Fig. 1. The higher-dose groups were
obtained in a separate experiment using
an identical injection schedule ofMISO.
Figs 3 and 4 show dose-response curves
for regrowth delay of the RIF-1 tumour
in mice given various single doses of CY.
24
_ 20
-
z
w
7L
16 _
x 12
w8 i,
4
0
0
/
/1 ,'
/
- ,,1~
50 100 150
DOSE OF CYCLOPHOSPHAMIDE (mg/kg)
FIG. 3.-The effect ofsaline (0) or prolonged
low-level MISO (0) on regrowth delay of
the RIF-1 tumouraftervarious doses ofCY.
Points show geometric means + s.e.
Tumours grown i.m. in the leg.
The groups given MISO were subject, to
exactly the same repeated injection proto-
col of MISO every 30 min, and were
injected with CY 4 h after the first MISO
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FiG. 4.- The effect of the same saline +CY
(O) and MISO+CY (0) treatments as in
Fig. 3 on regrowth delay of the RIF-Il
tumour growing intradermally in the flank.
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FIG. 5.-The number of white blood cells in
the peripheral blood 4 days after treat-
ments with saline+CY (O, A) or pro-
longed MIS exposure+CY (, ). Error
bars are + s.e. Circles and triangles rep-
resent separate experiments.
injection. The last MISO injection was
given 3 h after the CY injection. Blood
levels in both experiments were monitored
as before, and found to be similar to those
shown in Fig. 1.
One of the purposes of these two
experiments was to examine the influence
of the different types ofhypoxia in RIF-1
tumours implanted i.m. and i.d. The
radiation response of i.m. tumours indi-
cates that they contain 25-100% of cells
at an intermediate level of oxygenation,
whereas intradermally (i.d.) implanted
RIF-1 tumours have a radiation response
which shows that they have few (1%)
fully (radiobiologically) hypoxic cells
(Brown et al., 1980). However, it can be
seen from a comparison of Figs 3 and 4
that both i.m. and i.d. implanted tumours
were sensitized about equally to the
cytotoxic action of CY.
Fig. 5 shows results from two separate
experiments in which WBC counts were
made at the nadir ofthe response after CY
injection (4 days). One set of data was
obtained on the same mice that were used
for the tumour response in Fig. 3. As with
the CFU-S assay (Fig. 2), it is apparent
that MISO, under the given conditions,
had no cytotoxicity by itself and no
sensitization to CY.
Melphalan
The regrowth-delay assay was used to
study the effect of multiple MISO injec-
tions on the cytotoxicity of melphalan
(L-PAM). The MISO doses chosen were
lower than those in the CY experiment, in
an attempt to match the human levels
more closely at early times after drug
administration. This was successful (Fig. 6
lower panel). L-PAM treatments produced
considerable tumour regression, with or
without multiple MISO, but when the
tumours finally regrew, their growth rate
was the same as untreated tumours, show-
ing no "tumour bed effect". These growth
curves allowed accurate determinations of
the time each group of tumours took to
reach 4 x their volume at the time oftreat-
ment. The mean values for each treatment
group are shown in Fig. 6 (upper panels).
The mice received multiple injections of
saline or MISO every 30 min, in combina-
tion with various doses ofL-PAM. In both
experiments multiple MISO was found to
be dose-modifying, giving an enhancement
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FIG. 6.-The upper panels show the effect in two separate experiments of different doses of L-PAM,
with (0) or without (0) prolonged low-level MISO exposure, on the time to reach 4 x treatment
volume. Also shown is the enhancement of L-PAM cytoxicity by a large single dose of MISO
(750 mg/kg) 30 min before L-PAM injection (A). Error bars + s.e. The plasma levels of MISO in
one ofthese low-level experiments are shown in the lower panel in which, the dashed line represents
a typical human drug profile after a single 7g oral administration of MISO (Urtasun et al., 1977).
ratio of 2. The effect of a large single
dose of MISO (750 mg/kg) is also shown
for comparison. The MISO levels achieved
with multiple injections in these experi-
ments are shown in Fig. 6 (lower panel).
The response of a normal tissue to
multiple MISO and L-PAM was deter-
mined using WBC counts. Fig. 7 shows
the effect of multiple MISO injections. In
2 experiments no significant enhancement
was apparent. The dose ofL-PAMrequired
to kill 50% of mice bearing the RIF-1
tumour in the leg was not affected by the
addition of multiple MISO (ER =1 0).
An LD50 of 11.5 + 1'3 mg/kg (95% confi-
dence limits) was obtained in each case.
The experiment was repeated with non-
tumour bearing mice with the same result.
DISCUSSION
The principal shortcoming of nitro-
imidazole radiosensitizers in radiation
therapy is that while radiosensitization
depends mainly on the drug concentration
in the tumour at the moment ofirradiation
(Adams et al., 1975) the dose-limiting
neurotoxicity shows a dependence on the
total tissue exposure to the drug. Conroy
et al. (1979) have shown that the total
exposure dose of MISO to produce
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neuropathy is similar in mouse and man,
at about 60 mm. h. The mouse can tolerate
a much higher administered dose because
of a shorter MISO half-life. An obvious
consequence of this is that much lower
drug doses must be used in the clinic than
in small experimental animals, with the
expectation ofalowerenhancement ratio.
The interaction between MISO and
alkylating agents in tumours appears to
show a very different dependence on
MISO exposure. While the duration ofthe
MISO level is not a major factor in
determining radiosensitization, it is one of
the main determinants of chemosensitiza-
tion. The effectiveness of prolonged ex-
posure to low levels of MISO (Figs 1, 3,
4 & 6) suggests that both the duration of
MISO exposure before CY treatment and
peak MISO concentration are important
in determining the chemosensitization, at
least over the range studied. Our results
show that the prolonged exposure to low
levels of MISO, close to those which are
now used clinically with minimal compli-
cations, gives large ERs when used with
CY or L-PAM.
The absence ofenhanced toxicity in the
normal tissues studied is particularly
encouraging and intriguing. The reason
for this lack of enhancement is unclear,
but is does appear that low MISO levels
do not enhance toxicity in normal tissues.
Additional evidence for this is provided by
experiments with mouse testis (Hirst et al.,
unpublished). Doses of MISO below 300
mg/kg gave no enhancement of CY
toxicity, whereas enhancement at higher
doses was considerable.
While our highest doses of alkylating
agents are higher than can be tolerated in
man on a mg/kg basis, good enhancement
of tumour response can be achieved at
doses which are well tolerated. For
example, 50 mg/kg CY in a single dose
will notnormally leadto severehaematolo-
gical impairment, but at that dose, MISO
pretreatment would be expected to yield
a therapeutic gain. A more appropriate
basis for comparison between mouse and
human dosage of alkylating agents may
be g/m2, in which case the best thera-
peutic gain should be obtained at doses
below the maximum clinically achievable.
In this case MISO might be more effective
in combination with several smaller doses
of alkylating agents.
The dependence of enhancement on
both MISO concentration and duration of
exposure might suggest a mechanism
related to MISO cytotoxicity to hypoxic
cells. It has been shown (Moore et al., 1976)
that both contact time and drug concen-
tration influence the hypoxic cell cyto-
toxicity of MISO in vitro. Conroy et al.
(1980) showed that prolonged exposure
in vivo to MISO alone at levels similar to
those used in the present study reduced
the surviving fraction of EMT6/Ro cells
to 0-5. However, no cytotoxicity was
observed in the EMT6/St/lu tumour after
prolonged exposure to low MISO levels
(achieved by nephrectomy) in the mouse
(Brown & Yu, 1979) and, as can be seen
in Figs 1, 3 & 4, no effect of multiple
MISO alone was seen in the RIF-1 tumour
in the present study. It seems unlikely,
therefore, that enhancement by MISO is
simply an additive toxicity.
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It has been shown that preincubation
of mammalian cells with MISO under
hypoxic conditions sensitizes these cells to
subsequent exposure to alkylating agents
(Stratford et al., 1980). Our data suggest
similarities between the "preincubation
effect" and the in vivo enhancement of
cytotoxicity. In each case, cells must be
exposed to MISO before the alkylating
agent to show enhancement. However,
hypoxia is a requirement for the "pre-
incubation effect" (Stratford et al., 1980),
whereas our data show that different
levels of hypoxia, which produce different
responses to radiation (Brown et al., 1980),
do not affect chemosensitization (Figs 3 &
4). This, and the observation that normal
tissues can be sensitized by large single
doses of MISO (Law et al., (1981), suggest
that an in vivo manifestation of the
preincubation effect is not the only
mechanism involved.
While a fuller understanding of the
process of MISO enhancement of alkylat-
ing-agent toxicity is highly desirable ifthe
greatest clinical benefit is to be obtained
with these combinations, our data give
cause for optimism that, under currently
acceptable conditions of administration,
MISO can be combined with at least two
widely used alkylating agents to achieve
greater killing of tumour cells without a
significant increase in normal-tissue com-
plications.
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